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Determination of the earliest molecular changes that occur
during the process of cellular transformation is of intense
interest to the field of tumor biology but represents a con-
siderable technical challenge in that it is not normally ame-
nable to pathological examination. As the transition from
melanocyte hyperplasia to primary cutaneous melanoma
often occurs within dysplastic nevi at the dermal–epidermal
junction on sun exposed sites of the skin, it presents a
unique opportunity to examine these initial stages of tumor
progression. Aberrant changes associated with this transi-
tion can be identified via gene expression profiling using
high-density DNA microarrays probed with samples pre-
pared from melanocytic lesions or cell lines (Carr et al, 2003)
or conversely using immunohistochemical staining to deter-
mine expression in tissue section microarrays from defined
stages (Pacifico et al, 2004). Genes identified as being dif-
ferentially expressed in this way provide prognostic markers
as well as insight into the process of cellular transformation.
The combination of both of these techniques were used in
the report of Zhou et al (2005), in order to discover genes
highly upregulated in melanocytic lesions. Comparison of
metastatic tumor nodules with benign nevi has found over
190 genes potentially implicated in this process of early
stage transformation, with the osteopontin gene already
recognized for its involvement in transformation of a number
of diverse tumor types (Wai and Kuo, 2004) showing the
highest abundance of differential expression.
Five phases have been proposed for the progression of
melanoma based on clinical and histopathological features
which include common acquired and congenital nevi with
normal melanocytes, dysplastic nevus with structural and
architectural atypia, early radial growth phase (RGP) me-
lanoma, advanced vertical growth phase (VGP) melanoma
with competence for metastasis, and metastatic melanoma
(Hsu et al, 2002). The genetic alterations responsible for
each of these stages in the development and stepwise pro-
gression of melanoma are still largely unclear, although the
discovery of the mutually exclusive BRAF and NRAS gene
mutations in most melanomas has provided evidence for the
involvement of mitogen-activated protein kinase (MAPK) ac-
tivation in this progression pathway. The transition from RGP
to VGP melanoma is a biologically critical step in melanoma
and a variety of changes in sections of melanocytic lesions
and in cultured cells have been observed at the molecular
level that may help explain the RGP–VGP switch. Several
adhesion molecules have been studied, in particular the in-
tegrins that are non-covalently associated, heterodimeric,
cell surface glycoproteins with a and b subunits. The most
notable pair relevant for melanoma metastasis is the avb3
vitronectin receptor and it is now recognized that the b3
subunit is a specific melanoma-associated marker that dis-
tinguishes RGP from VGP melanomas (Seftor, 1998).
Osteopontin was first identified as a transformation re-
lated secreted glyco-phosphoprotein that can act as a
cytokine and is a multifunctional component of the extra-
cellular matrix (Wai and Kuo, 2004). It is present at high
levels in non-collagenous bone and can also mediate cell
adhesion, migration, and chemotaxis. Multiple isoforms for
osteopontin have been detected that can range up to 75 kD
with both alternative splicing and extensive post-transla-
tional modifications leading to the appearance of tissue
specific or condition dependent variant forms of the protein.
An RGD amino acid binding motif that mediates ligation
of cell surface integrin subunits is present six residues
upstream from an efficient thrombin cleavage site in the
osteopontin peptide sequence. The production of an
N-terminal phosphorylated subfragment after specific pro-
teolysis is required for efficient engagement of integrin re-
ceptors, with melanoma cells shown to preferentially bind to
thrombin cleaved osteopontin through the avb3 hetero-
dimer expressed on their surface. Receptor binding allows
osteopontin to mediate adhesion to the cell matrix as well
as activate cellular second messengers in signal transduct-
ion pathways that help prevent apoptosis.
The clinical relevance of osteopontin expression to me-
lanoma progression and metastasis was investigated by
Zhou et al (2005) by examination of a range of melanocytic
lesions. These included benign nevi, dysplastic nevi, me-
lanoma in situ (RGP), invasive primary melanomas at differ-
ent stages (VGP), and metastatic melanomas. Osteopontin
was not readily detectable in normal nevi with perhaps weak
detection in nests within dysplastic nevi and melanoma
in situ; however, 72% of invasive primary biopsies expressed
this protein at high levels, implicating its involvement in the
invasive process of tumor progression. This expression was
not correlated with tumor thickness and no significant dif-
ference between metastatic melanomas and primary me-
lanomas was found. Detailed experimental examination of
the role osteopontin plays in the first steps of invasion re-
main, however preliminary functional testing using siRNA
ablation of mRNA in a melanoma cell line was found to
compromise cell growth.
Abbreviations: MAPK, mitogen-activated protein kinase; MMP,
matrix metalloproteinase; RGP, radial growth phase; VGP, vertical
growth phase
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The clinical identification of osteopontin as an early can-
didate in melanoma progression using tumor biopsy material
of patients is reinforced in the findings of several experimen-
tal models focusing on the signaling pathways directing me-
lanoma metastasis. Introduction of the B16 melanoma cell
line into osteopontin-knockout mice by ventral or femoral in-
jection resulted in significantly reduced tumor formation in
the bone, adrenal gland, and lung and also when directly
implanted into the bone marrow space (Ohyama et al, 2004),
indicating host osteopontin production can increase tumor
cell invasion. In other studies using subcutaneous injection of
B16 melanoma cells to examine the process of tumor
growth, a significant increase in tumor burden was seen up-
on treatment of these cells with human osteopontin protein
purified from milk (Philip et al, 2001). Further characterization
of osteopontin protein treatment of B16 cells in vitro dem-
onstrated greater cell growth, migration, and invasive ca-
pacities along with the induction of matrix metalloproteinases
(MMP) that degrade the extracellular matrix during tissue re-
pair, tumor invasion, and metastasis. The increased produc-
tion of pro-MMP2 and activation of MMP2 in treated cells
was shown to occur through an NF-kB dependent pathway.
Moreover, these effects were shown to be mediated through
the high affinity interaction of osteopontin with the avb3 in-
tegrin expressed by these cells via suppression using a
blocking antibody or disrupting RGD containing peptides.
Genetic analysis of interspecific hybrids of the fish Xi-
phophorus has identified the Xmrk gene as a melanoma
inducing oncogene which is structurally related to the mam-
malian epidermal growth factor receptor gene, Egfr (Me-
ierjohann et al, 2004). Expression of the Xmrk gene induces
melanocyte cell growth, resistance to apoptosis, and de-
differentiation mediated by several signal transduction path-
ways. A tyrosine kinase receptor gene chimera produced
through the fusion of the extracellular part of the Egfr with
the Xmrk cytoplasmic domain (HERmrk) has been used to
analyze signaling specific to the pigment cell lineage via
transfection of mouse melanocytes. Stimulation of this chi-
meric receptor resulted in a MAPK-dependent initiation of
depigmentation coupled with the appearance of a trans-
formed phenotype. A differential display approach was tak-
en to identify genes upregulated by activation of HERmrk in
these cells as candidates involved in the pathway of cellular
transformation and survival (Geissinger et al, 2002). Notably,
these experiments identified the osteopontin mRNA as in-
creasing within 2 h of HERmrk signaling, with up to 20-fold
induction at 4 h (Geissinger et al, 2002; Meierjohann et al,
2004). Addition of osteopontin protein to the melan-a strain
of murine melanocytes allowed them to survive in three-
dimensional collagen gels whereas untreated cells under-
went apoptosis. The use of blocking antibodies again
showed that the major receptor for osteopontin in these
mouse melanocytes was the avb3 integrin. As a result of
these experiments it has been proposed that the autocrine
production of osteopontin in transformed melanocytic cells
may be an important factor that allows invasion and survival
in the dermal environment as a first step toward malignancy
(Meierjohann et al, 2004).
The endogenous production of osteopontin or interaction
of exogenous osteopontin deposited within the extracellular
matrix with cell adhesion molecules such as avb3 integrin
expressed by melanoma cells as they progress toward ma-
lignancy is reminiscent of another early life event. The im-
plantation of the blastocyst after fertilization is dependent
upon adhesion to the endometrial surface lining and invasion
of the endometrium. Mounting evidence has implied that this
attachment process requires the co-expression of avb3 and
the ligand osteopontin, thereby determining the entire future
development of an embryo (Johnson et al, 2003), showing
the link between the processes of embryogenesis and
tumorigenesis. The transcriptional regulatory factors that
contribute to osteopontin expression during these two proc-
esses, the multiple pathways that are activated including
MAPK (Meierjohann et al, 2004), NF-kB (Philip et al, 2001),
and c-src (Chellaiah et al, 1996), together with the identifi-
cation of the downstream genes once osteopontin mediated
avb3 ligation has taken place, is vital to our understanding of
the steps that occur during melanoma progression. The
subsequent production of other extracellular matrix proteins
in response to osteopontin-avb3 cellular stimulation such as
osteonectin (Sturm et al, 2002), which is a counter adhesive
protein that may be required to balance the adhesive prop-
erties of osteopontin to allow the detachment and move-
ment essential for invasion, are the next steps that need to
be taken to characterize the pathway of melanoma pro-
gression. These incremental steps in our understanding of
the initial events in tumor progression are vital to move for-
ward towards an effective treatment for this disease.
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